Department of Radiotherpay, Hangzhou Cancer Hospital, Hangzhou 310006,China (Zhu LC,Xia B,Deng QH,Chen SM);Center for Translational Medicine (Zhu LC,Xu YS,Zhang SR),Department of Oncology (Ma SL),Hangzhou First People′s Hospital, Nanjing Medical University, Hangzhou 310006,China
Abstract Radiotherapy is a critical approach for the comprehensive treatment of non-small cell lung cancer. Deep understanding of the individualized radiosensitivity of lung cancer patients plays a pivotal role in the selection of radiotherapy dosage and regime and establishment of comprehensive therapeutic strategies. Currently, multiple researchers have identified a variety of biomarkers in predicting the radiosensitivity of lung cancer patients. In this article, research progress on the biomarkers in predicting radiosensitivity of non-small cell lung cancer was reviewed.
Corresponding Authors:
Ma Shenglin,Email:mashenglin@medmail.com.cn
Cite this article:
Zhu Lucheng,Xu Yasi,Xia Bing et al. Research progress on biomarkers in predicting radiosensitivity of non-small cell lung cancer[J]. Chinese Journal of Radiation Oncology, 2018, 27(4): 420-424.
Zhu Lucheng,Xu Yasi,Xia Bing et al. Research progress on biomarkers in predicting radiosensitivity of non-small cell lung cancer[J]. Chinese Journal of Radiation Oncology, 2018, 27(4): 420-424.
[1] Pollom EL,Qian YS,Durkee BY,et al. Hypofractionated intensity-modulated radiotherapy for patients with non-small-cell lung cancer[J].Clin Lung Cancer,2016,17(6):588-594.DOI:10.1016/j.cllc.2016.05.024. [2] Bischoff P,Altmeyer A,Dumont F.Radiosensitising agents for the radiotherapy of cancer:advances in traditional and hypoxia targeted radiosensitisers[J].Expert Opin Ther Pat,2009,19(5):643-662.DOI:10.1517/13543770902824172. [3] Impicciatore G,Sancilio S,Miscia S,et al. Nutlins and ionizing radiation in cancer therapy[J].Curr Pharm Des,2010,16(12):1427-1442.DOI:10.2174/138161210791033932. [4] Roper N,Stensland KD,Hendricks R,et al. The landscape of precision cancer medicine clinical trials in the United States[J].Cancer Treat Rev,2015,41(5):385-390.DOI:10.1016/j.ctrv.2015.02.009. [5] Torres-Roca JF.A molecular assay of tumor radiosensitivity:a roadmap towards biology-based personalized radiation therapy[J].Per Med,2012,9(5):547-557.DOI:10.2217/pme.12.55. [6] Torres-Roca JF,Eschrich S,Zhao HY,et al. Prediction of radiation sensitivity using a gene expression classifier[J].Cancer Res,2005,65(16):7169-7176.DOI:10.1158/0008-5472.CAN-05-0656. [7] Eschrich S,Zhang HL,Zhao HY,et al. Systems biology modeling of the radiation sensitivity network:a biomarker discovery platform[J].Int J Radiat Oncol Biol Phys,2009,75(2):497-505.DOI:10.1016/j.ijrobp.2009.05.056. [8] Scott JG,Berglund A,Schell MJ,et al. A genome-based model for adjusting radiotherapy dose (GARD):a retrospective,cohort-based study[J].Lancet Oncol,2017,18(2):202-211.DOI:10.1016/S1470-2045(16)30648-9. [9] Gettinger SN,Kowanetz M,Koeppen H,et al. Molecular,immune and histopathological characterization of NSCLC based on PDL1 expression on tumor and immune cells and association with response to the anti-PDL1 antibody MPDL3280A[J].J Clin Oncol,2015,33(15 Suppl):3015.DOI:10.1200/jco.2015.33.15_suppl.3015. [10] Garon EB,Rizvi NA,Hui R,et al. Pembrolizumab for the treatment of non-small-cell lung cancer[J].N Engl J Med,2015,372(21):2018-2028.DOI:10.1056/NEJMoa1501824. [11] Herbst RS,Baas P,Kim DW,et al. Pembrolizumab versus docetaxel for previously treated,PD-L1-positive,advanced non-small-cell lung cancer (KEYNOTE-010):a randomised controlled trial[J].Lancet,2016,387(10027):1540-1550.DOI:10.1016/S0140-6736(15)01281-7. [12] Borghaei H,Paz-Ares L,Horn L,et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer[J].N Engl J Med,2015,373(17):1627-1639.DOI:10.1056/NEJMoa1507643. [13] Rizvi NA,Mazières J,Planchard D,et al. Activity and safety of nivolumab,an anti-PD-1 immune checkpoint inhibitor,for patients with advanced,refractory squamous non-small-cell lung cancer (CheckMate 063):a phase 2,single-arm trial[J].Lancet Oncol,2015,16(3):257-265.DOI:10.1016/S1470-2045(15)70054-9. [14] Brahmer J,Reckamp KL,Baas P,et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer[J].N Engl J Med,2015,373(2):123-135.DOI:10.1056/NEJMoa1504627. [15] Spigel DR,Chaft JE,Gettinger SN,et al. Clinical activity and safety from a phase Ⅱ study (FIR) of MPDL3280A (anti-PDL1) in PD-L1–selected patients with non-small cell lung cancer (NSCLC)[A]//ASCO Annual Meeting[C].Chicago:American Society of Clinical Oncology,2015. [16] Fehrenbacher L,Spira A,Ballinger M,et al. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR):a multicentre,open-label,phase 2 randomised controlled trial[J].Lancet,2016,387(10030):1837-1846.DOI:10.1016/S0140-6736(16)00587-0. [17] Herbst RS,Soria JC,Kowanetz M,et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients[J].Nature,2014,515(7528):563-567.DOI:10.1038/nature14011. [18] Rizvi NA,Brahmer JR,Ou SHI,et al. Safety and clinical activity of MEDI4736,an anti-programmed cell death-ligand 1(PD-L1) antibody,in patients with non-small cell lung cancer (NSCLC)[A]//Proceedings of american society of clinical oncology annual meeting[C].Chicago:ASCO,2015. [19] Bernstein MB,Krishnan S,Hodge JW,et al. Immunotherapy and stereotactic ablative radiotherapy (ISABR):a curative approach?[J].Nat Rev Clin Oncol,2016,13(8):516-524.DOI:10.1038/nrclinonc.2016.30. [20] Salama AKS,Postow MA,Salama JK.Irradiation and immunotherapy:from concept to the clinic[J].Cancer,2016,122(11):1659-1671.DOI:10.1002/cncr.29889. [21] Lugade AA,Sorensen EW,Gerber SA,et al. Radiation-induced IFN-γ production within the tumor microenvironment influences antitumor immunity[J].J Immunol,2008,180(5):3132-3139.DOI:10.4049/jimmunol.180.5.3132. [22] Vrankar M,Kern I,Stanic K.118P:PD-L1 expression as prognostic factor for survival after chemoradiotherapy of locally advanced NSCLC[J].J Thorac Oncol,2016,11(4 Suppl):S107.DOI:10.1016/S1556-0864(16)30231-3. [23] Zhao J,Zhang P,Wang JH,et al. Plasma levels of soluble programmed death ligand-1 may be associated with overall survival in nonsmall cell lung cancer patients receiving thoracic radiotherapy[J].Medicine (Baltimore),2017,96(7):e6102.DOI:10.1097/MD.0000000000006102. [24] Frixa T,Donzelli S,Blandino G.Oncogenic MicroRNAs:key players in malignant transformation[J].Cancers (Basel),2015,7(4):2466-2485.DOI:10.3390/cancers7040904. [25] Hobert O.Gene regulation by transcription factors and microRNAs[J].Science,2008,319(5871):1785-1786.DOI:10.1126/science.1151651. [26] Humphries B,Wang ZS,Yang CF.The role of microRNAs in metal carcinogen-induced cell malignant transformation and tumorigenesis[J].Food Chem Toxicol,2016,98:58-65.DOI:10.1016/j.fct.2016.02.012. [27] Iorio MV,Croce CM.MicroRNA dysregulation in cancer:diagnostics,monitoring and therapeutics. A comprehensive review[J].EMBO Mol Med,2012,4(3):143-159.DOI:10.1002/emmm.201100209. [28] Oom AL,Humphries BA,Yang CF.MicroRNAs:novel players in cancer diagnosis and therapies[J].Biomed Res Int,2014,2014:959461.DOI:10.1155/2014/959461. [29] Su ZY,Yang ZZ,Xu YQ,et al. MicroRNAs in apoptosis,autophagy and necroptosis[J].Oncotarget,2015,6(11):8474-8490.DOI:10.18632/oncotarget.3523. [30] Suh YE,Raulf N,Gken J,et al. MicroRNA-196a promotes an oncogenic effect in head and neck cancer cells by suppressing annexin A1 and enhancing radioresistance[J].Int J Cancer,2015,137(5):1021-1034.DOI:10.1002/ijc.29397. [31] Li G,Wang YY,Liu Y,et al.miR-185-3p regulates nasopharyngeal carcinoma radioresistance by targeting WNT2B in vitro[J].Cancer Sci,2014,105(12):1560-1568.DOI:10.1111/cas.12555. [32] Oh JS,Kim JJ,Byun JY,et al. Lin28-let7 modulates radiosensitivity of human cancer cells with activation of K-Ras[J].Int J Radiat Oncol Biol Phys,2010,76(1):5-8.DOI:10.1016/j.ijrobp.2009.08.028. [33] Salim H,Akbar NS,Zong D,et al.miRNA-214 modulates radiotherapy response of non-small cell lung cancer cells through regulation of p38MAPK,apoptosis and senescence[J].Br J Cancer,2012,107(8):1361-1373.DOI:10.1038/bjc.2012.382. [34] Yan D,Ng WL,Zhang XM,et al. Targeting DNA-PKcs and ATM with miR-101 sensitizes tumors to radiation[J/OL].PLoS One,2010,5(7):e11397.DOI:10.1371/journal.pone.0011397. [35] Hatano K,Kumar B,Zhang YG,et al. A functional screen identifies miRNAs that inhibit DNA repair and sensitize prostate cancer cells to ionizing radiation[J].Nucleic Acids Res,2015,43(8):4075-4086.DOI:10.1093/nar/gkv273. [36] Wang XC,Du LQ,Tian LL,et al. Expression and function of miRNA in postoperative radiotherapy sensitive and resistant patients of non-small cell lung cancer[J].Lung Cancer,2011,72(1):92-99.DOI:10.1016/j.lungcan.2010.07.014. [37] Lan FM,Yue X,Ren G,et al.miR-15a/16 enhances radiation sensitivity of non-small cell lung cancer cells by targeting the TLR1/NF-κB signaling pathway[J].Int J Radiat Oncol Biol Phys,2015,91(1):73-81.DOI:10.1016/j.ijrobp.2014.09.021. [38] Chen X,Xu YM,Liao XY,et al. Plasma miRNAs in predicting radiosensitivity in non-small cell lung cancer[J].Tumor Biol,2016,37(9):11927-11936.DOI:10.1007/s13277-016-5052-8. [39] Alix-Panabières C,Pantel K.Clinical applications of circulating tumor cells and circulating tumor DNA as liquid biopsy[J].Cancer Discov,2016,6(5):479-491.DOI:10.1158/2159-8290.CD-15-1483. [40] Bortolin MT,Tedeschi R,Bidoli E,et al. Cell-free DNA as a prognostic marker in stage Ⅰ non-small-cell lung cancer patients undergoing stereotactic body radiotherapy[J].Biomarkers,2015,20(6-7):422-428.DOI:10.3109/1354750X.2015.1094139. [41] Dorsey JF,Kao GD,MacArthur KM,et al. Tracking viable circulating tumor cells (CTCs) in the peripheral blood of non-small cell lung cancer (NSCLC) patients undergoing definitive radiation therapy:pilot study results[J].Cancer,2015,121(1):139-149.DOI:10.1002/cncr.28975. [42] Bettegowda C,Sausen M,Leary RJ,et al. Detection of circulating tumor DNA in early-and late-stage human malignancies[J].Sci Transl Med,2014,6(224):224ra224.DOI:10.1126/scitranslmed.3007094. [43] Newman AM,Bratman SV,To J,et al. An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage[J].Nat Med,2014,20(5):548-554.DOI:10.1038/nm.3519. [44] Wulfkuhle J,Espina V,Liotta L,et al. Genomic and proteomic technologies for individualisation and improvement of cancer treatment[J].Eur J Cancer,2004,40(17):2623-2632.DOI:10.1016/j.ejca.2004.05.020. [45] Fu ZZ,Gu T,Fu BH,et al. Relationship of serum levels of VEGF and TGF-β1 with radiosensitivity of elderly patients with unresectable non-small cell lung cancer[J].Tumor Biol,2014,35(5):4785-4789.DOI:10.1007/s13277-014-1628-3. [46] Huang W,Ding X,Li B,et al. Serum biomarkers analyzed by LC-MS/MS as predictors for short outcome of non-small cell lung cancer patients treated with chemoradiotherapy[J].Neoplasma,2013,60(1):11-18.DOI:10.4149/neo_2013_002. [47] Gupta NC,Frank AR,Dewan NA,et al. Solitary pulmonary nodules:detection of malignancy with PET with 2-[F-18]-fluoro-2-deoxy-D-glucose[J].Radiology,1992,184(2):441-444.DOI:10.1148/radiology.184.2.1620844. [48] Kubota K,Matsuzawa T,Fujiwara T,et al. Differential diagnosis of lung tumor with positron emission tomography:a prospective study[J].J Nucl Med,1990,31(12):1927-1932. [49] Bradley J,Thorstad WL,Mutic S,et al. Impact of FDG-PET on radiation therapy volume delineation in non-small-cell lung cancer[J].Int J Radiat Oncol Biol Phys,2004,59(1):78-86.DOI:10.1016/j.ijrobp.2003.10.044. [50] Hirsch AE,DeNunzio N,Levin-Epstein R,et al. In regards to Dennis and Duncan:radiation oncology in undergraduate medical education:a literature review (Int J Radiat Oncol Biol Phys,2010,76:649-655)[J].Int J Radiat Oncol Biol Phys,2010,78(2):639.DOI:10.1016/j.ijrobp.2010.03.041. [51] Burdick MJ,Stephans KL,Reddy CA,et al. Maximum standardized uptake value from staging FDG-PET/CT does not predict treatment outcome for early-stage non-small-cell lung cancer treated with stereotactic body radiotherapy[J].Int J Radiat Oncol Biol Phys,2010,78(4):1033-1039.DOI:10.1016/j.ijrobp.2009.09.081. [52] Takeda A,Yokosuka N,Ohashi T,et al. The maximum standardized uptake value (SUVmax) on FDG-PET is a strong predictor of local recurrence for localized non-small-cell lung cancer after stereotactic body radiotherapy (SBRT)[J].Radiother Oncol,2011,101(2):291-297.DOI:10.1016/j.radonc.2011.08.008. [53] Wiegman EM,Pruim J,Ubbels JF,et al.18F-FDG PET during stereotactic body radiotherapy for stage Ⅰ lung tumours cannot predict outcome:a pilot study[J].Eur J Nucl Med Mol Imaging,2011,38(6):1059-1063.DOI:10.1007/s00259-010-1706-8. [54] Lovinfosse P,Janvary ZL,Coucke P,et al. FDG PET/CT texture analysis for predicting the outcome of lung cancer treated by stereotactic body radiation therapy. FDG PET/CT texture analysis for predicting the outcome of lung cancer treated by stereotactic body radiation therapy[J].Eur J Nucl Med Mol Imaging,2016,43(8):1453-1460.DOI:10.1007/s00259-016-3314-8. [55] Dong M,Liu J,Sun XR,et al. Prognositc significance of SUVmax on pretreatment 18F-FDG PET/CT in early-stage non-small cell lung cancer treated with stereotactic body radiotherapy:a meta-analysis[J].J Med Imag Radiat Oncol,2017,61(5):652-659.DOI:10.1111/1754-9485.12599.
2018, Vol. 27 
